Merck has announced the expansion of its single use current good manufacturing process (cGMP) facility with the addition of the Mobius 2000L single-use bioreactor
With the new upstream suite at its Biodevelopment Center in France, Merck said that it can offer full process line cGMP manufacturing.
Udit Batra, CEO, life science at Merck, said: "Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production.
“Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing - at either an existing facility or one we help them design."
Merck said that it can also advance recombinant products from cell line development through to late-stage clinical production and allows clients to leverage its Provantage End-to-End Services.
Merck's Provantage End-to-End solution is a suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialisation.